Hims & Hers Health, Inc. operates a comprehensive digital health platform that seamlessly links individuals with licensed medical professionals for virtual consultations and ongoing care. Through its user-friendly websites and mobile app, the company delivers a diverse portfolio of health and wellness solutions directly to consumers. This includes access to recurring prescription medications, alongside a wide selection of over-the-counter drugs, devices, cosmetics, and dietary supplements. Its core focus areas are general wellness, sexual health, skincare, and hair care. Specific…
The world is moving towards longevity escape velocity $HIMS continues to deploy the perfect infrastructure to bring longevity as a service to the masses The market has 0 clue Beautiful set up that will make financial analysts once again reconsider their existence…
@NighthawkTradez Yeah sell that along with all the $IREN you were buying from $50-$60 and $HIMS at $60
$HIMS has 0 competition You'll find out once the price action confirms it and as always, it'll be too late https://t.co/f7XzHVO2EI
$HIMS and $DUOL are re-accelerating Q3 earnings will be very interesting
Companies with no actual competition: 1. $PLTR 2. $DUOL 3. $AMD 4. $SPOT 5. $HIMS 6. $TSLA 7. $NAUT 8. $IBRX
@himshouse This is huge for $HIMS with approx 25-30% of men over the age of 30 years old being candidates for TRT ie low testosterone which is typically considered to be under 300 ng/dL however many medical professionals might recommend TRT for someone under 400 ng/DL which…
15 analysts rate HIMS Hold on consensus.
Consensus price target: $31.15 (+6.93% upside from $29.13)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| Boughton Soleil Chief Legal Officer | Oct 14, 2026 | Sale | 3,461 | $100.58K |
| Okupe Oluyemi Chief Financial Officer | Oct 1, 2026 | Sale | 2,000 | $59.4K |
| Boughton Soleil Chief Legal Officer | Sep 30, 2026 | Sale | 3,461 | $100.96K |
| Okupe Oluyemi Chief Financial Officer | Sep 22, 2026 | Sale | 29,277 | $876.85K |
| Okupe Oluyemi Chief Financial Officer | Sep 17, 2026 | Sale | 12,313 | $354.86K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $2.35B | +59% | $128.37M |
| 2024 | $1.48B | +69.33% | $126.04M |
| 2023 | $872M | +65.49% | $-23.55M |
Stock data for HIMS: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics